GRGrifols GRFS · NASDAQ
$7.64 +1.33% (+$0.10)
- Market cap
- 5.69B €
- Enterprise value
- 13.7B €
- P/E
- 12.6x
- Forward P/E
- 9.7x
- PEG
- 0.1x
- P/S
- 0.8x
- P/FCF
- 7.9x
- EV/EBITDA
- 7.8x
- ROIC
- 5.5%
- Gross margin
- 37.2%
- Net margin
- 6.1%
- Dividend yield
- 1.25%
- Payout ratio
- 15.7%
- Net debt/EBITDA
- 4.6x
- Beta
- 1.19
- Free float
- 98.7%
About the company
Grifols, S.A. is a global Spanish pharmaceutical and biotechnology company specializing in the production of plasma-derived medicines and healthcare products. The company focuses on producing immunoglobulins, albumin, and other plasma-based products that are essential for the treatment of various diseases, including immunological and neurological disorders. Grifols also develops diagnostic tools and systems for hospitals and clinics. The company has a broad global presence and operates in over 30 countries worldwide.
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Jose Ignacio Abia Buenache
Employees
25,258
Headquarters
Barcelona
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number